Pfizer Charts Post-Pandemic Course: R&D Pivot Follows Mixed 2025 Financials
Pfizer navigates a year of transition as declining COVID product sales and looming patent cliffs pressure revenue. The pharmaceutical giant is betting its future on a revitalized R&D strategy and newly acquired obesity assets from Metsera to drive growth beyond 2026.